| RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E) PI Poulikakos, Y Persaud, M Janakiraman, X Kong, C Ng, G Moriceau, ... Nature 480 (7377), 387, 2011 | 1668 | 2011 |
| Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy H Shi, W Hugo, X Kong, A Hong, RC Koya, G Moriceau, T Chodon, R Guo, ... Cancer discovery, 2013 | 1075 | 2013 |
| Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance H Shi, G Moriceau, X Kong, MK Lee, H Lee, RC Koya, C Ng, T Chodon, ... Nature communications 3, 724, 2012 | 827 | 2012 |
| Non-genomic and immune evolution of melanoma acquiring MAPKi resistance W Hugo, H Shi, L Sun, M Piva, C Song, X Kong, G Moriceau, A Hong, ... Cell 162 (6), 1271-1285, 2015 | 624 | 2015 |
| Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction G Moriceau, W Hugo, A Hong, H Shi, X Kong, CY Clarissa, RC Koya, ... Cancer cell 27 (2), 240-256, 2015 | 382 | 2015 |
| MDM4 is a key therapeutic target in cutaneous melanoma A Gembarska, F Luciani, C Fedele, EA Russell, M Dewaele, S Villar, ... Nature medicine 18 (8), 1239, 2012 | 370 | 2012 |
| A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition H Shi, A Hong, X Kong, RC Koya, C Song, G Moriceau, W Hugo, ... Cancer discovery, 2013 | 190 | 2013 |
| Recurrent tumor cell-intrinsic and-extrinsic alterations during MAPKi-induced melanoma regression and early adaptation C Song, M Piva, L Sun, A Hong, G Moriceau, X Kong, H Zhang, S Lomeli, ... Cancer discovery, CD-17-0401, 2017 | 156 | 2017 |
| Vemurafenib resistance reprograms melanoma cells towards glutamine dependence JE Hernandez-Davies, TQ Tran, MA Reid, KR Rosales, XH Lowman, ... Journal of translational medicine 13 (1), 210, 2015 | 123 | 2015 |
| Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors H Shi, G Moriceau, X Kong, RC Koya, R Nazarian, GM Pupo, ... Cancer discovery, 2012 | 116 | 2012 |
| Exploiting drug addiction mechanisms to select against MAPKi-resistant melanoma A Hong, G Moriceau, L Sun, S Lomeli, M Piva, R Damoiseaux, SL Holmen, ... Cancer discovery, 2017 | 111 | 2017 |
| Exploiting drug addiction mechanisms to select against A Hong, G Moriceau, L Sun, S Lomeli, M Piva, R Damoiseaux, SL Holmen, ... | 111* | |
| Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process G Moriceau, B Ory, L Mitrofan, C Riganti, F Blanchard, R Brion, C Charrier, ... Cancer Research, canres. 0578.2010, 2010 | 109 | 2010 |
| Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014; 4: 80–93. doi: 10.1158/2159-8290 H Shi, W Hugo, X Kong, A Hong, RC Koya, G Moriceau, T Chodon, R Guo, ... CD-13-0642.[PMC free article][Abstract][Cross Ref], 0 | 106 | |
| Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy Y Wang, S Liu, Z Yang, AP Algazi, SH Lomeli, Y Wang, M Othus, A Hong, ... Cancer Cell 39 (10), 1375-1387. e6, 2021 | 95 | 2021 |
| JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma B Titz, A Lomova, A Le, W Hugo, X Kong, J Ten Hoeve, M Friedman, H Shi, ... Cell discovery 2, 16028, 2016 | 68 | 2016 |
| Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity A Hong, M Piva, S Liu, W Hugo, SH Lomeli, V Zoete, CE Randolph, ... Cancer Discovery 11 (3), 714-735, 2021 | 54 | 2021 |
| Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models B Gobin, G Moriceau, B Ory, C Charrier, R Brion, F Blanchard, F Redini, ... PloS one 9 (3), e90795, 2014 | 52 | 2014 |
| Therapeutic approach of primary bone tumours by bisphosphonates G Moriceau, B Ory, B Gobin, F Verrecchia, F Gouin, F Blanchard, F Redini, ... Current Pharmaceutical Design 16 (27), 2981-2987, 2010 | 48 | 2010 |
| Plasticity of extrachromosomal and intrachromosomal BRAF amplifications in overcoming targeted therapy dosage challenges K Song, JK Minami, A Huang, SR Dehkordi, SH Lomeli, J Luebeck, ... Cancer discovery, 2021 | 44 | 2021 |
